|29 April, 2019

GSK and Neopharma partner to accelerate supply of medicines to patients in the UAE

GSK partners with Neopharma to localize its Secondary Packaging stage - the last phase of the manufacturing process before distribution and sale.

  • The partnership reduces the manufacturing process lead time to only three months, offering UAE patients faster access to six widely-prescribed medicines. 

ABU DHABI:

The global science-led healthcare company GlaxoSmithKline (GSK) and Neopharma, a leading global pharmaceutical company in the United Arab Emirates (UAE), announced today the launch of their new partnership creating localization and manufacturing opportunities in the UAE. The partnership establishes Neopharma as GSK’s third-party manufacturer for handling the Secondary Packaging process (final manufacturing stage) for six of GSK’s most highly demanded medicine brands in the UAE.

The localization of production means that GSK will be able to procure, package and supply those medications more quickly to the UAE market, ensuring a steadier and more seamless supply, enabling a more efficient response to address any emerging supply gaps. The move will also positively impact patients by ensuring they are able to access the GSK medicines that doctors prescribe for them.

The ceremony, held at the British Embassy in Abu Dhabi, was officiated by His Excellency Patrick Moody, the British Ambassador to the United Arab Emirates, and by Sameh Elfangary, General Manager at GSK in the Gulf, and Dr B.R. Shetty, Founder and Chairman of Neopharma. In attendance were also high-ranking officials and representatives, including His Excellency Khalfan AlSuwaidi, Industrial Property Director at Ministry of Economy, and Her Excellency Dr Ola Ghaleb Al Ahdab, Pharmaceutical Advisor at Drug Department, Ministry of Health and Prevention.

The UK Ambassador to the UAE, His Excellency Mr. Patrick Moody, said “I am very proud to see the commitment of one of our most important UK innovator Pharma companies to the UAE vision.  This will solidify important partnerships working with the UAE Ministry of Health and Prevention”.   He added “This links the strategies and development visions of both countries, especially the objectives of the UAE Vision 2021, which aims to strengthen the status of the country as a major commercial and logistical hub in the region, and the UK’s Industrial Strategy and Export Strategy, which aims to strengthen the UK's position as a global exporter”.  

Sameh Elfangary, General Manager at GSK in the Gulf, said: “At GSK, we are committed to ensuring the quality, safety and reliable supply of our products. The collaboration will be fully operational by early 2020 in the UAE and will cover medications that are in high demand locally. This operation will help ensure continuity in supply and improved patient access to GSK medicines in the market.”

He continued: “We are grateful to have partnered with a trusted pharmaceutical company with a large global footprint, such as Neopharma, and are already exploring possibilities for expansion plans within the next two years.”

Dr B.R. Shetty, Founder and Chairman of Neopharma, added: “It is a landmark to have a collaboration with another leading innovator company such as GSK as a partner. We have become a partner of choice for MNCs over a period of time, which reaffirms Neopharma’s commitment to maintain global quality and manufacturing standards that are compliant to stringent regulatory requirements.”

This partnership is reinforcing UAE’s vision to become a pharmaceutical manufacturing hub in the region.

-Ends-

About GSK

GSK is science-led global healthcare company with a special purpose-- to help people do more, feel better, live longer. Globally and regionally, we have a proven track-record for providing high quality medicines, vaccines and consumer products. GSK has a 300-year global legacy and more than 70 years of local presence in the Gulf region. Today, GSK is one of the most innovative and best performing companies in the region, providing medical well-being to millions of people in the region. 

About Neopharma

Neopharma LLC, one of the largest pharmaceutical companies in MENA region with 100% subsidiaries in USA, Japan, Brazil, and India. A vertically integrated business, comprising of API, R&D and Formulation facilities in emerging and regulated markets. This enable us to deliver innovative and quality generic products in a timely manner at affordable prices in over 50 countries worldwide. Neopharma's global presence is supported by 7 manufacturing facilities spread across 4 continents delivering a wide range of branded and generic formulations, and active pharmaceutical ingredients (APIs).  The therapeutic segments covered are acute and chronic therapies.

Media Enquiries:
Alia Karim
Hill+Knowlton Strategies
Alia.Karim@hkstrategies.com 
+971 56 501 9503

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases